Literature DB >> 19687512

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor.

Anne F Riddell1, Keith Gomez, Carolyn M Millar, Gillian Mellars, Saher Gill, Simon A Brown, Megan Sutherland, Mike A Laffan, Thomas A J McKinnon.   

Abstract

Investigation of 3 families with bleeding symptoms demonstrated a defect in the collagen-binding activity of von Willebrand factor (VWF) in association with a normal VWF multimeric pattern. Genetic analysis showed affected persons to be heterozygous for mutations in the A3 domain of VWF: S1731T, W1745C, and S1783A. One person showed compound heterozygosity for W1745C and R760H. W1745C and S1783A have not been reported previously. The mutations were reproduced by site-directed mutagenesis and mutant VWF expressed in HEK293T cells. Collagen-binding activity measured by immunosorbent assay varied according to collagen type: W1745C and S1783A were associated with a pronounced binding defect to both type I and type III collagen, whereas the principal abnormality in S1731T patients was a reduction in binding to type I collagen only. The multimer pattern and distribution of mutant proteins were indistinguishable from wild-type recombinant VWF, confirming that the defect in collagen binding resulted from the loss of affinity at the binding site and not impairment of high-molecular-weight multimer formation. Our findings demonstrate that mutations causing an abnormality in the binding of VWF to collagen may contribute to clinically significant bleeding symptoms. We propose that isolated collagen-binding defects are classified as a distinct subtype of von Willebrand disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687512     DOI: 10.1182/blood-2008-10-184317

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Von Willebrand disease in the United States: a perspective from Wisconsin.

Authors:  Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Daniel B Bellissimo; Sandra L Haberichter; Robert R Montgomery
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

2.  Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Authors:  V H Flood; J C Gill; P A Christopherson; D B Bellissimo; K D Friedman; S L Haberichter; S R Lentz; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

3.  Implications for collagen I chain registry from the structure of the collagen von Willebrand factor A3 domain complex.

Authors:  T Harma C Brondijk; Dominique Bihan; Richard W Farndale; Eric G Huizinga
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-21       Impact factor: 11.205

4.  Crucial role for the VWF A1 domain in binding to type IV collagen.

Authors:  Veronica H Flood; Abraham C Schlauderaff; Sandra L Haberichter; Tricia L Slobodianuk; Paula M Jacobi; Daniel B Bellissimo; Pamela A Christopherson; Kenneth D Friedman; Joan Cox Gill; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2015-02-06       Impact factor: 22.113

5.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

6.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 7.  Advances in the diagnosis and treatment of Von Willebrand disease.

Authors:  Ruchika Sharma; Veronica H Flood
Journal:  Blood       Date:  2017-11-30       Impact factor: 22.113

8.  Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.

Authors:  V H Flood; C A Lederman; J S Wren; P A Christopherson; K D Friedman; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2010-03-23       Impact factor: 5.824

Review 9.  Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

Authors:  G Castaman; A Hillarp; A Goodeve
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

10.  Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease.

Authors:  D M Larsen; S L Haberichter; J C Gill; A D Shapiro; V H Flood
Journal:  Haemophilia       Date:  2013-03-18       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.